Journal
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
Volume 18, Issue 4, Pages 250-255Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/0891988705281883
Keywords
Alzheimer's disease; genetic testing; apolipoprotein E; risk assessment
Categories
Funding
- NCRR NIH HHS [M01 RR00533] Funding Source: Medline
- NHGRI NIH HHS [HG/AG02213] Funding Source: Medline
- NIA NIH HHS [AG13846, AG09029] Funding Source: Medline
Ask authors/readers for more resources
As genetic risk factors continue to be identified for common, complex adult-onset diseases, it will become increasingly important to understand if, how, and when to translate these discoveries into clinical practice. This article provides an overview of and results to date from the REVEAL study, a multisite randomized clinical trial (n = 162) examining the impact of a genetic risk assessment program, including apolipoprotein E genotype disclosure, for adult children of people with Alzheimer's disease. The study's rationale and procedures are described, including the generation of numerical lifetime risk curves for use in the education and counseling protocol. Findings are summarized across numerous study questions, including (1) who seeks genetic risk assessment and why, (2) how apolipoprotein E results affect risk perceptions, (3) the psychological impact of genetic risk assessment, and (4) how risk information affects participants' subsequent health and insurance behaviors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available